These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2280 related items for PubMed ID: 12051571

  • 1. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC.
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic profile of dexloxiglumide.
    Persiani S, D'Amato M, Jakate A, Roy P, Wangsa J, Kapil R, Rovati LC.
    Clin Pharmacokinet; 2006 May; 45(12):1177-88. PubMed ID: 17112294
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT.
    Eur J Clin Pharmacol; 2001 May; 56(11):805-11. PubMed ID: 11294370
    [Abstract] [Full Text] [Related]

  • 4. The single-dose pharmacokinetics of the novel CCK1 receptor antagonist, dexloxiglumide, are not influenced by age and gender.
    Roy P, Wangsa J, Patel A, Nolting A, Persiani S, Abramowitz W, Kapil R.
    Int J Clin Pharmacol Ther; 2005 Sep; 43(9):444-51. PubMed ID: 16163898
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects.
    Webber C, Roth A, Persiani S, Peard AJ, Makovec F, Kapil RP, John BA, Holding JD, D'amato M, Cybulski ZR, Chasseaud LF, Rovati LC.
    Xenobiotica; 2003 Jun; 33(6):625-41. PubMed ID: 12851039
    [Abstract] [Full Text] [Related]

  • 6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
    Xu M, Ni Y, Zhou Y, He X, Li H, Chen H, Li W.
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M.
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
    Li M, Shi A, Pang H, Xue W, Li Y, Cao G, Yan B, Dong F, Li K, Xiao W, He G, Du G, Hu X.
    J Ethnopharmacol; 2014 Oct 28; 156():210-5. PubMed ID: 25219601
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
    Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della Cioppa G.
    Eur J Clin Pharmacol; 1999 Apr 28; 55(2):131-8. PubMed ID: 10335908
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G, Angeles-Moreno AP, Contreras-Zavala L, Morales-Martínez M, Rivera-Espinosa L.
    Clin Ther; 2009 Sep 28; 31(9):2002-11. PubMed ID: 19843490
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
    Martin P, Oliver S, Kennedy SJ, Partridge E, Hutchison M, Clarke D, Giles P.
    Clin Ther; 2012 Jan 28; 34(1):221-37. PubMed ID: 22206795
    [Abstract] [Full Text] [Related]

  • 17. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, Fishman P.
    Int J Clin Pharmacol Ther; 2004 Oct 28; 42(10):534-42. PubMed ID: 15516022
    [Abstract] [Full Text] [Related]

  • 18. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.
    Allen A, Bygate E, Vousden M, Oliver S, Johnson M, Ward C, Cheon A, Choo YS, Kim I.
    Antimicrob Agents Chemother; 2001 Feb 28; 45(2):540-5. PubMed ID: 11158752
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK, Cheng G, Tang J, Song J, Peng WX.
    Clin Ther; 2009 May 28; 31(5):1022-36. PubMed ID: 19539103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 114.